Catalyst Pharmaceutical Partners Inc.
355 Alhambra Circle
Suite 1370
Coral Gables,
FL 33134
United States - Map
Phone: 305-529-2522
Fax: 305-529-0933
Web Site: http://www.catalystpharma.com
| Catalyst Pharmaceutical Partners, Inc., a development-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs for the treatment of drug addiction and obsessive-compulsive disorders. Its products include CPP-109, a chemical compound gamma-vinyl-GABA/vigabatrin, a Phase II clinical trial product for the treatment of cocaine addiction. The company also conducts a Phase II clinical trial of CPP-109 to evaluate its use in the treatment of methamphetamine addiction. In addition, it has a license agreement with Brookhaven Science Associates, LLC on various patents and patent applications relating to the use of vigabatrin as a treatment for cocaine and other addictions. Catalyst Pharmaceutical Partners, Inc. was founded in 2002 and is based in Coral Gables, Florida. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. Patrick J. McEnany , 61
Co-Founder, Chairman, Chief Exec. Officer and Pres |
$
343.00K | N/A | Dr. Hubert E. Huckel M.D., 77
Co-Founder, Director, Member of the Audit Committee, Member of Compensation Committee and Member of Nominating & Corp. Governance Committee |
$
20.00K | N/A | Mr. Jack Weinstein , 53
Chief Financial Officer, VP and Treasurer |
$
217.00K | N/A | Dr. Steven R. Miller Ph.D., 47
Chief Scientific Officer and VP of Pharmaceutical Devel. & Project Management |
$
221.00K | N/A | Mr. M. Douglas Winship , 59
VP of Regulatory Operations |
$
196.00K | N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.16% Nasdaq 
0.02 (2.63%) 
Profile
